Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 4/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308857 | 1.00 | CTSC (0.44) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL1308859 | 1.00 | CTSC (0.44) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL1310109 | 0.82 | TAAR1 (0.53) | CTSCCYP1A2TAAR1SLC18A2SIGMAR1 | |
| SCHEMBL1086155 | 0.82 | TAAR1 (0.53) | CTSCCYP1A2TAAR1SLC18A2SIGMAR1 | |
| SCHEMBL5031408 | 0.82 | CTSC (0.46) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL1308687 | 0.82 | CTSC (0.42) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL8776735 | 0.82 | CTSC (0.42) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL5031407 | 0.82 | CTSC (0.46) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL8776731 | 0.82 | CTSC (0.42) | CTSCEPHX1CYP1A2TAAR1SLC18A2 | |
| SCHEMBL1529264 | 0.82 | CTSC (0.46) | CTSCEPHX1CYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | disclosed |
| US-6774211-B1 | Peptide antiangiogenic drugs | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | disclosed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0564972-B1 | Peptides with N-terminal modifications having bradykinin antagonistic activity | HOECHST AG (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0455133-B1 | Peptide antagonists of bradykinin | HOECHST AG (DE) | 1997-03-05 | — | — | EP | disclosed |
| EP-0413277-B1 | Peptide antagonists of bradykinin | HOECHST AG (DE) | 1994-11-23 | — | — | EP | disclosed |
| EP-0564972-A2 | Peptides with N-terminal modifications having bradykinin antagonistic activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-10-13 | — | — | EP | disclosed |
| EP-0455133-A2 | Peptide antagonists of bradykinin | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-06 | — | — | EP | disclosed |
| EP-0413277-A1 | Peptide antagonists of bradykinin | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | CTSC 767/4885EPHX1 3113/4885CYP1A2 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.